Published in Neuropharmacology on March 04, 2013
Psychedelics. Pharmacol Rev (2016) 1.00
Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. Behav Brain Res (2014) 0.95
Serotonergic hallucinogens as translational models relevant to schizophrenia. Int J Neuropsychopharmacol (2013) 0.82
Fluorescent knock-in mice to decipher the physiopathological role of G protein-coupled receptors. Front Pharmacol (2015) 0.82
Sex-dependent impacts of low-level lead exposure and prenatal stress on impulsive choice behavior and associated biochemical and neurochemical manifestations. Neurotoxicology (2014) 0.81
Cross-signaling in metabotropic glutamate 2 and serotonin 2A receptor heteromers in mammalian cells. Pflugers Arch (2016) 0.78
Nicotinic modulation of glutamate receptor function at nerve terminal level: a fine-tuning of synaptic signals. Front Pharmacol (2015) 0.77
Functional associations among G protein-coupled neurotransmitter receptors in the human brain. BMC Neurosci (2014) 0.77
APOE-ɛ4 Carrier Status and Donepezil Response in Patients with Alzheimer's Disease. J Alzheimers Dis (2015) 1.43
Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia? Curr Drug Targets CNS Neurol Disord (2002) 1.36
Metabotropic glutamate receptors in the control of mood disorders. CNS Neurol Disord Drug Targets (2007) 1.23
Antidepressant effects assessed using behavior maintained under a differential-reinforcement-of-low-rate (DRL) operant schedule. Neurosci Biobehav Rev (2005) 1.06
Default-mode-like network activation in awake rodents. PLoS One (2011) 1.04
Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039). J Pharmacol Exp Ther (2007) 1.03
Behavioral characterization of the mGlu group II/III receptor antagonist, LY-341495, in animal models of anxiety and depression. Eur J Pharmacol (2008) 0.98
Developing predictive CSF biomarkers-a challenge critical to success in Alzheimer's disease and neuropsychiatric translational medicine. Biochem Pharmacol (2011) 0.96
CNS distribution of metabotropic glutamate 2 and 3 receptors: transgenic mice and [³H]LY459477 autoradiography. Neuropharmacology (2012) 0.94
Awake rat pharmacological magnetic resonance imaging as a translational pharmacodynamic biomarker: metabotropic glutamate 2/3 agonist modulation of ketamine-induced blood oxygenation level dependence signals. J Pharmacol Exp Ther (2010) 0.90
Effects of a positive allosteric modulator of group II metabotropic glutamate receptors, LY487379, on cognitive flexibility and impulsive-like responding in rats. J Pharmacol Exp Ther (2010) 0.89
Heterocomplex formation of 5-HT2A-mGlu2 and its relevance for cellular signaling cascades. Neuropharmacology (2012) 0.89
LY-2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia. Curr Opin Investig Drugs (2010) 0.86
In vitro and in vivo evidence for a lack of interaction with dopamine D2 receptors by the metabotropic glutamate 2/3 receptor agonists 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-bicaroxylate monohydrate (LY354740) and (-)-2-oxa-4-aminobicyclo[3.1.0] Hexane-4,6-dicarboxylic acid (LY379268). J Pharmacol Exp Ther (2009) 0.86
AMPA receptor involvement in 5-hydroxytryptamine2A receptor-mediated pre-frontal cortical excitatory synaptic currents and DOI-induced head shakes. Prog Neuropsychopharmacol Biol Psychiatry (2007) 0.85
The mGlu2/3 receptor agonist LY354740 suppresses immobilization stress-induced increase in rat prefrontal cortical BDNF mRNA expression. Neurosci Lett (2006) 0.85
Modulation of DOI-induced increases in cortical BDNF expression by group II mGlu receptors. Pharmacol Biochem Behav (2002) 0.83
Group III metabotropic glutamate receptor agonists selectively suppress excitatory synaptic currents in the rat prefrontal cortex induced by 5-hydroxytryptamine2A receptor activation. J Pharmacol Exp Ther (2006) 0.81
Synthetic Aβ oligomers (Aβ(1-42) globulomer) modulate presynaptic calcium currents: prevention of Aβ-induced synaptic deficits by calcium channel blockers. Eur J Pharmacol (2013) 0.80
NOGO-66 receptor deficient mice show slow acquisition of spatial memory task performance. Neurosci Lett (2012) 0.78
Displacement of serotonin and dopamine transporters by venlafaxine extended release capsule at steady state: a [123I]2beta-carbomethoxy-3beta-(4-iodophenyl)-tropane single photon emission computed tomography imaging study. J Clin Psychopharmacol (2007) 0.78
Translational medicine special issue. Biochem Pharmacol (2011) 0.77
Identification and characterization of mGlu3 ligands using a high throughput FLIPR assay for detection of agonists, antagonists, and allosteric modulators. Comb Chem High Throughput Screen (2011) 0.77
Xanomeline modulation of the blood oxygenation level-dependent signal in awake rats: development of pharmacological magnetic resonance imaging as a translatable pharmacodynamic biomarker for central activity and dose selection. J Pharmacol Exp Ther (2012) 0.76
Establishment of a secondary screening assay for P/Q-type calcium channel blockers. Comb Chem High Throughput Screen (2013) 0.75
Population pharmacokinetics of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor ABT-384 in healthy volunteers following single and multiple dose regimens. Biopharm Drug Dispos (2014) 0.75